Juno Therapeutics Announces Pricing of Initial Public Offering

On December 18, 2014, Juno Therapeutics, Inc., a biopharmaceutical company developing cell-based cancer immunotherapies, announced the closing of its initial public offering of 12.7 million shares of common stock at a price to the public of $24.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase 1.7 million shares. Juno raised approximately $305 million from the offering. On a market capitalization basis, Juno's initial public offering was the largest biotech IPO in 2014 and, based on news reports at the time, it was the largest biotech IPO in the previous 10 years. The company is trading under the ticker symbol "JUNO."

Juno Therapeutics is a clinical-stage biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its goal is to revolutionize medicine by re-engaging the body's immune system to treat cancer.

News of Juno's successful IPO was widely reported in the business media, including coverage in The Wall Street Journal and The New York Times Dealbook.

Wilson Sonsini Goodrich & Rosati is advising Juno in the offering. WSGR's team is led by Patrick Schultheis and Michael Nordtvedt, and includes corporate team members Ben Dickson, Anitha Anne, and Amanda Pollard, and intellectual property/licensing team members Michael Rabson and Jane Taylor.